| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Not applicable. L-Leucine-13C6,15N is not used to measure pharmacological activity. It is employed as an analytical internal standard and metabolic tracer. Its purpose is to facilitate the precise quantification of unlabeled L-Leucine in biological samples using mass spectrometry. The pharmacological profile is identical to that of unlabeled L-Leucine.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an effect on a drug's pharmacokinetics and metabolic properties, it is a cause for concern [1].
Not applicable. L-Leucine-13C6,15N itself is not used for measuring biological activity. It is an analytical standard. However, the parent compound L-Leucine is an essential amino acid known to activate the mTOR signaling pathway. The labeled form is used as a tracer to study the metabolism of leucine itself. |
| ln Vivo |
Not applicable. L-Leucine-13C6,15N is an analytical standard and is not used for in vivo activity assays. However, it can be used as a metabolic tracer to study protein synthesis, amino acid turnover, and leucine metabolism in vivo. For this purpose, a tracer dose (e.g., 1-10 mg/kg) is administered, and its incorporation into proteins or its conversion to metabolites is tracked by mass spectrometry.
|
| Enzyme Assay |
L-Leucine-13C6,15N is used as an internal standard to quantify L-Leucine in biological samples. A stock solution is prepared in 0.1 M HCl, methanol, or water at a concentration of 1 mg/mL. To generate a calibration curve, blank biological matrix (e.g., plasma, urine, cell lysate) is spiked with known concentrations of unlabeled L-Leucine (0.1-1000 ng/mL) and a fixed concentration of L-Leucine-13C6,15N (e.g., 50 ng/mL). Proteins are precipitated by adding 3-5 volumes of ice-cold acetonitrile containing the internal standard. After centrifugation, the supernatant is diluted with 0.1% formic acid in water and analyzed by LC-MS/MS in MRM mode. The mass transitions are: L-Leucine (m/z 132 → 86) and L-Leucine-13C6,15N (m/z 139 → 92). The peak area ratio (analyte/IS) is plotted against the nominal concentration to generate a calibration curve. This method can be used to measure leucine in various matrices.
|
| Cell Assay |
For cellular metabolic studies, cells (e.g., hepatocytes, cancer cells, or primary neurons) are cultured in leucine‑free medium supplemented with a tracer amount of L-Leucine-13C6,15N (e.g., 50 uM) for 2-48 hours. The labeled leucine is taken up by the cells and can be incorporated into newly synthesized proteins. At the end of the labeling period, proteins are extracted from the cells, hydrolyzed, and the resulting free amino acids are derivatized for analysis by GC‑MS or LC‑MS. The enrichment of the labeled leucine in the protein pool can be measured to calculate the rate of protein synthesis. Alternatively, the cell culture medium can be analyzed to track the conversion of leucine into its metabolites (e.g., alpha-ketoisocaproate) by measuring the isotopic enrichment of the labeled metabolites.
|
| Animal Protocol |
L-Leucine-13C6,15N is used in metabolic tracer studies. Animals (e.g., male Sprague-Dawley rats, 200-250 g) are fasted overnight and then administered a tracer dose of L-Leucine-13C6,15N (e.g., 10 mg/kg) via an intravenous bolus or oral gavage. Blood samples are collected at predetermined times (e.g., 0, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24 hours post-dose). Plasma is separated, and the samples are processed as described for the cell-free protocol. The ratio of labeled to unlabeled leucine (the isotope enrichment) in the plasma is measured by LC-MS/MS over time. Compartmental modeling of the enrichment decay curve can be used to calculate the rate of appearance (Ra) and disappearance (Rd) of leucine in the whole body, providing a measure of protein turnover and amino acid catabolism. For studies of protein synthesis in specific tissues, a flooding dose of the labeled leucine is administered, and tissues (e.g., muscle, liver, brain) are collected 30-60 minutes later to measure the incorporation of the isotope into tissue proteins.
|
| ADME/Pharmacokinetics |
L-Leucine-13C6,15N (MW 138.15) is a stable isotope-labeled compound with high isotopic enrichment (typically 98 atom % ¹3C and 98 atom % ¹⁵N). It is typically 98% enriched with 13C and 15N. Its physicochemical properties are identical to those of unlabeled L-Leucine. It is water-soluble and stable. When used as a tracer, it is assumed to behave exactly like natural leucine in metabolic processes. It is primarily used in research applications and is not intended for therapeutic use.
|
| Toxicity/Toxicokinetics |
L-Leucine-13C6,15N is a non‑toxic, stable isotope‑labeled compound used as an analytical standard and tracer. At the concentrations used as an internal standard (ng/mL levels), it poses no toxicological risk. The unlabeled parent compound, L-Leucine, is an essential amino acid that is safe for consumption at nutritional levels. The labeled analog has no known acute or chronic toxicity at tracer doses.
|
| References | |
| Additional Infomation |
L-Leucine-13C6,15N (CAS 202406-52-8) is a high-purity, stable isotope-labeled internal standard for mass spectrometry. It is used for the accurate quantification of L-Leucine in research applications, including protein metabolism and amino acid analysis. The parent compound L-Leucine is an essential amino acid that activates the mTOR signaling pathway. The labeled analog has no therapeutic use.
|
| Molecular Formula |
13C6H1315NO2
|
|---|---|
| Molecular Weight |
138.12
|
| Exact Mass |
138.111
|
| CAS # |
202406-52-8
|
| Related CAS # |
L-Leucine;61-90-5
|
| PubChem CID |
16217567
|
| Appearance |
White to off-white solid powder
|
| Density |
1.0±0.1 g/cm3
|
| Index of Refraction |
1.463
|
| LogP |
-1.5
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
9
|
| Complexity |
101
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
[13CH3][13CH]([13CH3])[13CH2][13C@@H]([13C](=O)O)[15NH2]
|
| InChi Key |
ROHFNLRQFUQHCH-HUEJSTCGSA-N
|
| InChi Code |
InChI=1S/C6H13NO2/c1-4(2)3-5(7)6(8)9/h4-5H,3,7H2,1-2H3,(H,8,9)/t5-/m0/s1/i1+1,2+1,3+1,4+1,5+1,6+1,7+1
|
| Chemical Name |
(2S)-2-(15N)azanyl-4-(113C)methyl(1,2,3,4,5-13C5)pentanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 7.2401 mL | 36.2004 mL | 72.4008 mL | |
| 5 mM | 1.4480 mL | 7.2401 mL | 14.4802 mL | |
| 10 mM | 0.7240 mL | 3.6200 mL | 7.2401 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
